William C. Choi

Array ( [id] => 13440829 [patent_doc_number] => 20180271957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => METHODS TO TREAT CEROID LIPOFUSCINOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS [patent_app_type] => utility [patent_app_number] => 15/995055 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16705 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440827 [patent_doc_number] => 20180271956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => METHODS TO TREAT POMPE DISEASE USING A RECOMBINANT ADENO-ASSOCIATED VIRUS [patent_app_type] => utility [patent_app_number] => 15/995045 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15995045 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13428069 [patent_doc_number] => 20180265577 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ANTIBODIES TO TAU AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 15/993954 [patent_app_country] => US [patent_app_date] => 2018-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8918 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15993954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16886767 [patent_doc_number] => 20210172963 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => DETERMINING ONSET OF AMYOTROPHIC LATERAL SCLEROSIS [patent_app_type] => utility [patent_app_number] => 16/616853 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16616853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13440825 [patent_doc_number] => 20180271955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-27 [patent_title] => ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 15/989405 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16795 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15989405 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425095 [patent_doc_number] => 20180264090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => ADENO-ASSOCIATED VIRUS MEDIATED GENE TRANSFER TO THE CENTRAL NERVOUS SYSTEM [patent_app_type] => utility [patent_app_number] => 15/987490 [patent_app_country] => US [patent_app_date] => 2018-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15987490 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13606959 [patent_doc_number] => 20180355028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => Antibodies to Alpha Synuclein [patent_app_type] => utility [patent_app_number] => 15/981008 [patent_app_country] => US [patent_app_date] => 2018-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15981008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012785 [patent_doc_number] => 20200181235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION [patent_app_type] => utility [patent_app_number] => 16/613339 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16613339 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14345383 [patent_doc_number] => 20190154664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => METHODS FOR DETERMINING THE EFFICACY PROFILE OF A DRUG CANDIDATE [patent_app_type] => utility [patent_app_number] => 15/977970 [patent_app_country] => US [patent_app_date] => 2018-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26908 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15977970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16087001 [patent_doc_number] => 20200197487 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => A TRIPLE-EFFECT COCKTAIL PRODUCED BY NEURAL STEM CELLS AS A NOVEL NEUROREPAIR THERAPY FOR CHRONIC STAGE CNS AUTOIMMUNITY [patent_app_type] => utility [patent_app_number] => 16/609882 [patent_app_country] => US [patent_app_date] => 2018-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16609882 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13399983 [patent_doc_number] => 20180251534 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => POLYPEPTIDES COMPRISING A MODIFIED BACTERIOPHAGE G3P AMINO ACID SEQUENCE WITH REDUCED IMMUNOGENICITY [patent_app_type] => utility [patent_app_number] => 15/971362 [patent_app_country] => US [patent_app_date] => 2018-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15971362 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16310837 [patent_doc_number] => 20200289575 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-17 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROLOGICAL DISORDERS OR CARDIOVASCULAR DISEASES, COMPRISING SRAGE-SECRETING STEM CELL [patent_app_type] => utility [patent_app_number] => 16/610135 [patent_app_country] => US [patent_app_date] => 2018-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17984 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16610135 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16053173 [patent_doc_number] => 20200188441 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-18 [patent_title] => METHODS AND COMPOSITIONS FOR REDUCING CORNEAL ENDOTHELIAL CELL LOSS [patent_app_type] => utility [patent_app_number] => 16/609184 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16609184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16086911 [patent_doc_number] => 20200197442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-25 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF ALZHEIMER'S DISEASE, COMPRISING STEM CELL SECRETING SRAGE [patent_app_type] => utility [patent_app_number] => 16/608813 [patent_app_country] => US [patent_app_date] => 2018-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14435 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16728113 [patent_doc_number] => 20210095260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => BI- OR MULTI-DIFFERENTIATED ORGANOID [patent_app_type] => utility [patent_app_number] => 16/608719 [patent_app_country] => US [patent_app_date] => 2018-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13922 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16608719 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221270 [patent_doc_number] => 20200246386 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 16/607112 [patent_app_country] => US [patent_app_date] => 2018-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30392 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16607112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527233 [patent_doc_number] => 20200055922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => IMMUNOGLOBULIN PRODUCTS FOR USE IN THE TREATMENT OF CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY [patent_app_type] => utility [patent_app_number] => 16/606605 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8467 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16606605 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16839469 [patent_doc_number] => 20210147481 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => PEPTIDE-BASED INHIBITORS OF MARK FAMILY PROTEINS [patent_app_type] => utility [patent_app_number] => 16/605302 [patent_app_country] => US [patent_app_date] => 2018-04-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12930 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 11 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16605302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13386395 [patent_doc_number] => 20180244739 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => PEPTIDE VACCINE FOR PREVENTION AND IMMUNOTHERAPY OF DEMENTIA OF THE ALZHEIMER'S TYPE [patent_app_type] => utility [patent_app_number] => 15/957798 [patent_app_country] => US [patent_app_date] => 2018-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35179 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 133 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15957798 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13359969 [patent_doc_number] => 20180231524 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-16 [patent_title] => IN VITRO METHODS OF IDENTIFYING MODULATORS OF NEUROMUSCULAR JUNCTION ACTIVITY [patent_app_type] => utility [patent_app_number] => 15/946905 [patent_app_country] => US [patent_app_date] => 2018-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13376 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15946905 [rel_patent_id] =>[rel_patent_doc_number] =>)